cd40 receptor epstein-barr viru oncoprotein lmp1 both member tnf-receptor famili share sever signal mediat includ traf2 traf3 depend cell lineag stage matur lmp1 cd40 synergist antagonist unrel effect previou public suggest both traf2 traf3 move lipid raft lmp1 express cd40 activ wherea proteolysi enhanc cd40 howev cd40-induc proteolysi traf2 report murin cell conflict data regard transloc traf2 lipid raft investig traf2 traf3 modif induc cd40 lmp1 signal panel human cell line lymphoid epitheli origin cd40 stimul mark redistribut traf2 buoyant raft fraction observ cell line associ similar redistribut traf3 contrast traf3 redistribut raft fraction lmp1 express moreov parallel chang subcellular distribut traf2 traf3 record electron microscopi signific decreas traf2 traf3 concentr trigger cd40 ligat observ cell line evid decreas requir neg feed-back jnk activ traf2 redistribut raft-like complex appear most signific event distinct cd40 lmp1 signal hand parallel influenc cd40 lmp1 traf3 redistribut consist function similar cd40-traf3 lmp1-traf3 ax
point mutat ra gene found larg number wide varieti human tumor oncogen ra mutant lock activ gtp-bound state lead constitut deregul activ ra function dogma ra oncogen domin wherebi mutat singl allel cell will predispos host cell transform regardless presenc normal allel challeng increas amount ra protooncogen abl inhibit activ n-ra oncogen activ elk nih 3t3 cell format foci abl determin inhibitori effect competit ra protooncogen n-ra oncogen occur first effector level membran process level effector level cytosol addit coexpress n-ra protooncogen thymic lymphoma induc n-ra oncogen associ increas level p107 p130 cyclin decreas level present report shown n-ra oncogen truli domin ra protooncogen compet activ depend cellular context
hyaluronidas substrat hyaluronan mainli explor solid tumor rare hematolog malign involv demonstr invas metastasi most case solid tumor role hyaluronidas cancer progress remain controversi on hyaluronidas hyal2 suspect involv first step degrad work hyal2 mrna total hyaluronidas express examin lymphoma tissu extract correl lymphoma subtyp real-time rt-pcr perform evalu hyal2 mrna hyaluronidas assai enzym-link sorbent assai result show hyal2 mrna express correl lymphoma diagnosi significantli lower high-grade lymphoma i.e diffus larg b-cell diffus lymphoma dlbcl sever form hyaluronidas detect zymographi total hyaluronidas activ detect tissu extract significantli differ accord tumor grade level correl lymphoma subtyp higher dlbcl moreov hyal2 mrna express invers correl 0.035 hyal2 gene local chromosom 3p21 contain candid tumor suppressor gene result suggest hyal2 prognost signific lymphoma antioncogen activ convers overexpress high-grade lymphoma favor involv tumor develop provid us target lymphoma therapi us ha-bind peptid
background children adolesc non-hodgkin lymphoma nhl matur b-cell leukemia b-all excel prognosi contemporari chemotherapi stratifi accord histolog subtyp clinic stage diseas howev small subset patient doe respond front-line therapi suffer earli relaps procedur retrospect analysi perform assess incid treatment outcom children relaps progress nhl b-all diagnos austria 1986 2003 22/234 result nine 140 6.5 patient b-cell nhl/b-all relaps progress fail initi treatment four underw hematopoiet stem cell transplant hsct second-line therapi two patient receiv intens chemotherapi alon three patient treatment palli eight nine patient di diseas four patient lymphoblast lymphoma lbl relaps progress treatment failur high-dose chemotherapi follow hsct perform two four patient anoth two patient receiv chemotherapi alon three four patient di resist diseas nine patient anaplast larg cell lymphoma alcl relaps progress fail first-line therapi six underw hsct autolog allogen current second complet remiss treatment three patient consist chemotherapi alon-thei di tumor progress conclus conclus patient earli relaps progress b-cell neoplasia lbl poor prognosi current treatment approach alcl respect chanc achiev sustain complet second remiss high-dose chemotherapi hsct
analyz relat hair dye us risk hodgkin's diseas non-hodgkin's lymphoma nhl multipl myeloma soft tissu sarcoma st hospit-base case-control studi conduct 1985 1997 northern itali case includ 158 patient histolog confirm incid 446 nhl 141 221 st control includ 295 patient acut nonneoplast condit compar us type hair dye odd ratio us 0.68 confid interv 0.40-1.18 1.03 0.73-1.44 nhl 1.17 0.70-1.97 0.73 0.45-1.17 st close uniti perman semiperman dye analyz separ analysi restrict women studi indic appreci associ us type hair dye risk nhl st
beta1-6 branch l-pha reactiv oligosaccharid on n-glycan structur plai import role biolog behavior variou tumor cell line report previous express l-pha reactiv oligosaccharid close associ prognosi patient human diffus larg cell lymphoma dlbcl present studi western blot analyz n-glycosyl pattern cd45 have l-pha reactiv oligosaccharid two case dlbcl express non-sialyl l-pha reactiv oligosaccharid cd45 found 180-210 kda 180-200 kda respect furthermor endoglycosidas treatment cd45 both case found 190 160 kda differ cd45 molecular weight two case due differ amount n-glycosyl clarifi biolog function cd45 n-glycan dlbcl analyz antiprolif effect human lymphoma cell bovin galectin-1 beta-galactosid-bind lectin-1 react cd45 n-glycan bovin galectin-1 stimul dlbcl cell line hbl-2 result inhibit growth vitro swainsonin potent inhibitor alpha-mannosidas catalyz synthesi complex type n-link oligosaccharid reduct express n-link oligosaccharid includ l-pha reactiv oligosaccharid cell surfac treatment prevent growth inhibit hbl-2 cell galectin-1 western blot on 190 kda isoform three cd45 isoform n-link oligosaccharid ligand galectin-1 detect reduct molecular weight kda treatment data suggest amount cd45 n-glycan reduc treatment reduct n-glycan prevent interact cd45 galectin-1 alter n-glycosyl cd45 regul lymphoma cell growth dlbcl through interact n-glycan cd45 galectin-1
us combin dna-microarrai tissu-microarrai tma analys identifi marker routin us predict outcom diffus larg-b-cell lymphoma dlcl patient gene express profil perform us dna-microarrai tumour biopsi sampl [31 dlcl follicular lymphoma patient dlcl t-cell leukemia/lymphoma-1a tcl1a mrna overexpress correl relaps dlcl patient tma analysi appli distinct seri formalin-fix paraffin-embed dlcl sampl show tcl1a immunoexpress correl higher relaps 0.02 lower 5-year overal surviv 0.009 rate moreov prognost valu tcl1a independ ipi seri data suggest tcl1a immunodetect independ marker advers outcom us routin set manag dlcl patient
report case primari effus lymphoma pel 75-year-old woman human immunodefici viru hepat viru present fever chest pain pericardi effus lymphoma cell posit cd20 cd79a neg cd3 cd10 genom human herp viru hhv-8 epstein-barr viru detect lymphoma cell cytogenet analysi show complex abnorm g-band techniqu spectral karyotyp sky analysi provid detail character chromosom aberr includ q21 q11 q32 q23 detect c-myc gene rearrang bcl-2 express treat successfulli six cours chop regimen present case demonstr rare categori pel associ hhv-8 c-myc gene rearrang addit sky analysi disclos cryptic chromosom abnorm involv 1q21 17q23
novo cd5-posit diffus larg b-cell lymphoma cd5 dlbcl regard differ clinicopatholog entiti cd5-neg dlbcl cd5 dlbcl mantl cell lymphoma mcl becaus few publish cytogenet studi novo cd5 dlbcl avail investig chromosom chang japanes patient novo cd5 dlbcl characterist cytogenet abnorm novo cd5 dlbcl high incid chromosom aberr affect 8p21 11q13 major chromosom breakpoint concentr 8p21 11q13 3q27 patient 8p21 aberr show aggress clinic featur includ advanc stage diseas elev serum ldh level poor perform statu inferior surviv curv compar patient 11q13 chang .043 chromosom abnorm both 8p21 11q13 observ same patient abnorm show differ chromosom gain loss result indic novo cd5 dlbcl occur previous unidentifi subgroup differ chromosom abnorm conflict result previou studi prognosi explain part differ chromosom chang
chromosom transloc involv immunoglobulin receptor loci usual disrupt silenc loci basi observ follicular lymphoma downstream heavi chain igh class switch recombin csr hypothes downstream csr-mediat chromosom transloc leav j-cmu transcript unit intact therebi still allow igm express igh allel involv transloc test hypothesi analyz biallel igh transloc igm-express cell line z-138 interphas fish dna fiber-fish long-distanc vectorett pcr dna sequenc on igh allel involv show break region juxtapos emu enhanc calpha enhanc cyclin gene igh allel contain breakpoint involv sgamma region wherea reciproc breakpoint 8q24 approxim centromer myc molecular analysi show igh allel harbor normal j-cmu complex respons igm express data show chromosom breakpoint occur downstream igh constant region necessarili interfer express
contrast younger patient prognosi elderli patient advanc hodgkin's diseas improv substanti year carri prospect random studi hd9 elderli compar beacopp regimen set standard copp-abvd februari 1993 1998 patient ag 66-75 year newli diagnos advanc stage recruit hd9 trial separ stratum hd9 elderli patient assign eight altern cycl copp abvd eight cycl beacopp baselin dose radiotherapi given initi bulki residu diseas total regist patient assess treat copp-abvd beacopp baselin signific differ copp-abvd beacopp term complet remiss overal surviv freedom treatment failur fftf year median follow-up month total patient di 14/26 patient treat copp-abvd 23/42 patient beacopp two patient treat copp-abvd nine patient treat beacopp di acut toxic hodgkin-specif fftf year copp-abvd beacopp 0.13 differ surviv regimen elderli patient
diagnos hodgkin diseas will surviv long-term past decad modifi hybrid consist cyclophosphamid 2.4-3.6g/m vincristin procarbazin prednison copp togeth adriamycin bleomycin vinblastin abv us treat patient littl data exist modifi hybrid impact male fertil eleven male patient treat copp-abv hybrid studi nine subject categor infertil semen analysi azoosperm associ fertil statu prepubert statu diagnosi gonadotropin statu despit lower dose cyclophosphamid treatment current copp/abv hybrid lead infertil major young men like procarbazin effect yet potent gonadotox agent respons outcom
patient stage non-hodgkin's lymphoma chronic hepat treat chemotherapi rituximab develop fatal reactiv hepat high viral load titer hepat dna demonstr dna sequenc analysi reveal presenc precor mutant strain hepat reactiv patient receiv rituxmab-base chemotherapi review role precor mutant viru strain result fatal complic discuss
acut long-term oral complic occur patient receiv mantl radiat therapi irradi head neck region hodgkin's diseas non-hodgkin's lymphoma consider data avail effect radiat therapi oral function qualiti life patient squamou cell carcinoma head neck inform lack similarli irradi lymphoma patient articl discuss rational studi design ongo random phase studi evalu role amifostin ethyol medimmun inc gaithersburg radiat protect patient receiv head neck irradi lymphoma investig lymphoma popul need improv understand extent problem impact patient' daili live function importantli fine-tune treatment manag approach minim morbid maxim surviv qualiti life patient crucial step
other previous shown us amifostin ethyol medimmun inc gaithersburg amelior certain regimen-relat toxic high-dose melphalan hd-mel autolog hematopoiet stem cell transplant set recent experi indic maximum toler dose hd-mel plu autolog hematopoiet stem cell transplant increas approxim 200 mg/m2 least 280 mg/m2 amifostin dose-limit toxic clearli identifi atrial fibril note sever patient phase trial us regimen report lymphoma myeloma nonetheless unlik singl agent therapi regardless dose will highli cur advanc hematolog malign us amifostin permit dose escal hd-mel beam bcnu/etoposid/arabinosylcytosin/hd-mel combin chemotherapi regimen befor autolog hematopoiet stem cell transplant select patient lymphoma patient entri start dose hd-mel 140 mg/m2 complet develop sever regimen-relat toxic trial ongo
past three decad chemotherapi chop cyclophosphamid/doxorubicin/vincristin/prednison standard treatment aggress non-hodgkin's lymphoma nhl minor chang have made regimen increas efficaci recent howev clinic trial shown signific improv outcom aggress nhl show benefit us dose-dens acceler schedul well ad rituximab standard chop regimen maintain rel dose intens deliv full dose chemotherapi schedul import principl achiev optim outcom treatment nhl clinic studi shown dose reduct delai result poorer outcom patient nhl case greater dose intens appear result greater overal progress-free surviv particular compress deliveri standard 21-dai chop dose dose-dens 14-dai schedul shown increas event-free surviv overal surviv both patient diffus larg b-cell lymphoma consequ chop-14 regimen dose intens greater standard regimen adopt oncologist treatment aggress nhl
background effect bacteri erad therapi fulli explain simpli elimin target bacteria on consid effect erad therapi pylori-neg case low-grade malign maltoma rectum present studi undertaken examin possibl mechan direct induct apoptosi tumor cell antibiot us bacteri erad therapi materi method cell lymphoma cell line 300-19 deriv balb/c mice co-cultur amoxicillin clarithromycin amoxicillin clarithromycin concentr equal 1/10 mic drug cell co-cultur 1/100 mic standard anti-tumor agent adriamycin vincristin cyclophosphamid serv posit control cell cultur antibiot anti-tumor agent serv control group analys perform time-cours chang cellular morpholog time-cours occurr dna fragment iii appear apoptot chang evalu trypan blue stain bcl-2 express examin immunoblot express tnfr1 fa fasl caspas-3 evalu immunoblot result cell treat amoxicillin clarithromycin show format apoptot bodi degener detach cell dose-depend manner dna fragment induc cell degre similar cell treat anti-tumor agent trypan blue stain demonstr apoptosi cell loss cell viabil bcl-2 express control group fasl express tnfr1 fa caspas-3 amoxicillin-treat group clarithromycin-treat group amoxicillin clarithromycin-treat group posit control group conclus antibiot us erad pylori directli induc apoptosi mous cell lymphoma cell action involv tnf system
background improv long-term surviv reduc toxic intermedi stage hodgkin's diseas patient compar effect involv field versu extend field irradi administ four cycl abvd regimen materi method two hundr ten hodgkin's diseas patient clinic stage risk factor iii risk factor enrol random studi hd94 four cours abvd regimen patient achiev complet remiss partial remiss randomli assign arm kaplan-meier method adopt estim overal surviv relaps-free surviv rf result median follow-up month rang 13-111 month respect arm rf respect arm conclus confirm efficaci four cycl abvd regimen suitabl dose intens radiotherapi consolid therapi intermedi stage hodgkin's diseas patient 99.5 found involv field radiotherapi result effect extend field acut toxic
69-year-old femal patient treat primari cn-lymphoma pcnsl start august 2002 gener condit allow high-dose methotrex mtx therapi radiotherapi administ first-line treatment csf involv manag intrathec ara-c gener condit cognit statu stabil improv month oral chemotherapi temozolomid 200 mg/m2 initi two cours toler problem patient's karnofski perform index improv mini-mental statu rose 27/30 csf-cell count elev cell/l sign mening relaps unfortun patient di unexpectedli suspect pulmonari embol conclud adjuv temozolomid chemotherapi improv gener condit cognit patient pcnsl gener condit poor long-term effect neurotox remain analys prospect trial well efficaci leptomening diseas
toxic involv gastrointestin tract common patient undergo aggress chemotherapi cancer howev uncommon develop sever ulcer perfor small intestin absenc direct involv bowel malign author describ two children develop sever gastrointestin complic requir surgic intervent initi chemotherapi non-hodgkin's lymphoma both patient evid small bowel involv lymphoma clinic stage
author investig diagnost valu cerebrospin fluid csf solubl cd27 scd27 leptomening involv non-hodgkin lymphoma nhl cytospin slide prepar csf sampl children treat nhl scd27 level determin sandwich elisa method us two cd27 monoclon antibodi 8/194 4.1 sampl consid tumor-posit cytolog mean scd27 valu 5.8 13.8 u/ml tumor-neg tumor-posit sampl respect .18 26/194 sampl fals posit 2/194 fals neg cutoff u/ml sensit specif posit predict valu 18.8 neg predict valu 98.8 accuraci 85.6 result valu ad scd27 determin cytolog csf examin remain question
endobronchi involv non-hodgkin lymphoma rare presenc advanc diseas 15-year-old boi present progress worsen dyspnea occasion hemoptysi week prior admiss three dai later intub due sever dyspnea complet atelectasi right lung fiberopt bronchoscopi disclos endobronchi mass almost occupi right main bronchu underw partial resect endobronchi tumor rigid bronchoscopi airwai stent us patient becaus sever tracheal obstruct tumor compromis airwai allevi combin chemotherapi tracheobronchi stent
object effect alcohol intak risk nhl unclear conduct popul-base case-control studi examin associ alcohol nhl risk method 613 nhl case 480 popul control sweden report averag consumpt beer wine liquor year befor studi uncondit logist regress us estim odd ratio correspond confid interv associ alcohol intak nhl risk result intak total alcohol beer wine liquor associ risk overal nhl differ risk nhl among habitu consum 19.1 ethanol per dai compar consum averag 0-2.2 ethanol per dai 1.2 0.8 1.7 ptrend 0.29 howev associ significantli posit among male 1.8 1.1 2.9 ptrend 0.06 total alcohol beer wine liquor intak associ major histopatholog subtyp nhl examin apart associ high wine consumpt increas risk chronic lymphocyt leukemia conclus alcohol doe appear major etiolog factor overal nhl nor common subtyp
radioimmunotherapi rit radionuclid conjug antibodi direct tumor associ antigen radioimmunoconjug administ therapeut regimen repres signific addit treatment non-hodgkin's lymphoma nhl rit offer sever advantag heterogen diseas foremost abil kill tumor cell adjac cell radioimmunoconjug bound cross-fire effect rit cytotox tumor cell inaccess antibodi express target antigen suffici quantiti antibodi bind radioimmunoconjug 90y-ibritumomab tiuxetan direct b-cell antigen cd20 phase iii clinic trial agent report overal respons rate complet respons rate patient relaps refractori indol transform nhl includ patient refractori rituximab median durat respons rang 13.9 month varieti rit approach under investig improv outcom patient nhl includ us radioimmunoconjug combin chemotherapi myeloabl therapeut strategi
epidemiolog data indic risk develop non-hodgkin lymphoma nhl hiv posit individu relat ag cd4 count i.e degre immunosuppress prognosi patient hiv-nhl shown link sever featur includ ag stage modifi ipi prior aid diagnosi cd4 count immunoblast patholog ldh haart us featur expect mixtur prognost factor relat both hiv nhl popul studi indic incid associ hiv-nhl reduc advent haart studi concur howev most popul-base studi yet shown signific improv surviv patient hiv-nhl haart optim chemotherapi patient unknown gener accept cn prophylaxi mandatori current good evid surviv benefit increas dose intens larg rct howev born mind larg randomis studi compar differ dose intens undertaken befor advent effect haart evid subset good prognosi patient benefit intens therapi given prognosi patient hiv consider improv haart necessarili assum same result appli regard chemotherapi dose intens evid surviv benefit addit haart chemotherapi retrospect like howev reason haart improv prognosi patient hiv reduc number patient dy hiv-relat ill whilst remiss lymphoma larg number patient earlier chemotherapi trial forgotten prognosi patient's nhl intim link prognosi respect hiv number patient hiv-nhl current few need trial chemotherapi particularli haart era prognosi point view hiv improv much particular issu dose intens need revisit patient overal prognosi improv commenc haart patient hiv-nhl manag specialist centr possibl manag part rct
aim studi defin initi characterist natur histori prognost factor patient ophthalmolog intraocular malign lymphoma patient treat institut curi lymphoma ophthalmolog orbit adnexa intraocular involv retrospect review patholog review case perform accord classif on hundr forti-five patient select studi patholog review show malt type lymphoma lymphoplasmocyt lymphoma diffus larg b-cell lymphoma ophthalmolog ocular site intra-orbit case conjunctiv case bilater involv case stage found case bone marrow involv median follow-up month 5-year df low-grade nhl high-grade nhl multivari analysi ag greater year elev ldh level stage high-grade histolog subgroup presenc b-symptom neg impact overal popul conclus median follow-up 7.5 year larg cohort patient repres on largest publish seri primari ophthalmolog intraocular malign lymphoma
angioimmunoblast t-cell lymphoma t-ail peripher t-cell lymphoma unknown etiolog previou clonal studi shown heterogen composit diseas vari restrict t-cell popul tumour first time singl studi same patholog materi analys lymphoid cell clonal occurr human herp virus epstein barr viru case 66.6 clonal three 16.6 clonal b-cell presenc lymphotrop viral genom hhv6 detect four lymph node biopsi t-ail patient tcrgamma clonal hhv8 found epstein barr genom found case signific associ t-cell clonal hhv-6 ebv infect b-cell clonal viru infect conclud t-ail biolog clinic heterogen entiti true natur remain clarifi
background purpos current view b-cell lymphoma genesi suggest sever exogen factor act multistep fashion predispos condit involv b-cell clonal expans potenti prelymphomat stage studi done investig extrahepat local hepat viru hcv gastric mucosa possibl involv besid helicobact pylori pylori possibl predispos factor plai role occurr gastric dysplasia lymphoprolifer gastriti carcinogenesi patient method well character seri patient chronic liver diseas complain gastric dyspepsia subject upper gastrointestin endoscopi histolog examin gastric biopsi studi preval serolog molecular marker hcv pylori patient' serum gastric tissu hcv-rna detect gastric tissu done show gastric dysplasia result histopatholog examin gastric biopsi reveal patient 44.4 chronic activ gastriti patient 33.4 chronic gastriti patient 22.2 gastric dysplasia chronic gastriti hepat viru patient 84.4 reactiv serum antibodi hcv-ab patient show polymeras chain reaction pcr posit helicobact pylori antibodi reactiv detect patient 82.2 pcr posit detect patient 53.3 both serum well gastric tissu seventeen twenti case show chronic activ gastriti serolog posit both pylori hcv patient show dysplasia patholog examin hcv-ab posit p-valu 0.32 seven patient serum hcv-rna posit p-valu 0.083 show hcv-rna posit gastric tissu nine patient gastric dysplast chang prove posit pylori dna both serum p-valu 0.027 tissu p-valu 0.029 conclus suggest hepat viru consid addit helicobact pylori anoth potenti infecti co-factor occurr gastric mucos dysplasia associ multistep hypothesi carcinogenesi
background purpos uncontrol growth invas distant spread characterist neoplast cell chang adhes molecul express loss express novo express function alter observ step aim present work studi express two adhes molecul [standard cd44 cd44s intercellular adhes molecul-1 icam-1 solubl form icam-1 sicam-1 adult dissemin non-hodgkin's lymphoma d-nhl correl find overal surviv patient method express cd44s icam-1 adhes molecul level sicam-1 studi case d-nhl includ case lymphoblast lymphoma lbl case burkitt's lymphoma on case diffus larg cell lymphoma dlcl case small lymphocyt lymphoma sll on case mantl cell lymphoma mcl ten appar healthi individu taken control group cd44s express evalu direct immunofluores icam-1 immunoperoxidas cyto-prep serum level sicam-1 elisa result icam-1 posit 6/34 case 17.6 d-nhl icam-1 express 2/15 13.3 low-grade nhl 4/19 high-grade lymphoma signific differ two group 0.6 cd44s express 13/34 case 38.2 d-nhl 4/15 26.6 low grade nhl 9/19 47.3 high grade lymphoma signific differ two group 0.2 serum level sicam-1 elev patient d-nhl compar healthi control statist signific differ &lt 0.001 median 1160 ng/ml rang 150 2500 ng/ml 375 ng/ml rang 270 620 ng/ml respect median sicam-1 patient high-grade d-nhl significantli 0.006 lower low-grade d-nhl median 890 ng/ml rang 150 1540 ng/ml 1440 ng/ml rang 380 2500 ng/ml respect .the median follow-up durat patient month statist signific differ achiev 0.8 compar overal surviv pattern d-nhl lymphoma patient posit neg express icam-1 scd44 express statist signific differ 0.9 found patient sicam 600 ng/ml month diagnosi conclus mark heterogen cell adhes molecul cam express nhl correl degre differenti malign lymphocyt howev exact signific find will requir function studi determin role cam subtyp nhl
background recent hypoth-size helicobact pylori pylori hepat viru hcv involv pathogenesi malign non-hodgkin's lymphoma nhl howev most studi carri adult patient basi observ sought determin preval infect pediatr nhl patient nation cancer institut nci whether clinic histopatholog pictur link presenc infecti agent patient method studi perform 119 pediatr nhl patient relaps case hematolog patient clinic nci januari 2002 juli 2003 thirti appar healthi children studi control search pylori igg antibodi us enzym immuno-assai eia procedur hcv investig eia detect antibodi revers transcriptas polymeras chain reaction rt-pcr presenc rna viral sequenc determin viral genotyp result antibodi pylori detect 51/119 43.2 none control group p&lt 0.001 wherea hcv antibodi found 21/119 17.6 nhl patient on control 3.3 p&lt 0.001 hcv rna detect 18/21 85.7 anti-hcv posit patient analyz neg anti-hcv posit control viral genotyp most frequent encount genotyp mix genotyp 1+4 detect four patient on patient show genotyp 1.no specif histolog subtyp extra-nodal present nor stage diseas relat pylori hcv posit older ag significantli relat pylori posit nhl patient posit correl presenc pylori antibodi complaint vomit diarrhea observ patient p&lt 0.001 conclus report high preval hcv pylori infect paediatr nhl patient nci concern hypothesi pathogenet role lymphomagenesi still unclear whether agent direct role malign transform pediatr lymphoma becaus typic nhl clinico-histolog featur associ hcv pylori lack
